Sivik Global Healthcare LLC Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Sivik Global Healthcare LLC trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 14.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,000 shares of the medical device company’s stock after selling 5,000 shares during the period. DexCom accounts for approximately 1.2% of Sivik Global Healthcare LLC’s holdings, making the stock its 29th largest position. Sivik Global Healthcare LLC’s holdings in DexCom were worth $3,401,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. International Assets Investment Management LLC bought a new position in shares of DexCom in the fourth quarter worth approximately $1,986,000. Atria Wealth Solutions Inc. boosted its holdings in DexCom by 73.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 6,290 shares of the medical device company’s stock worth $781,000 after buying an additional 2,674 shares during the period. Silver Oak Securities Incorporated purchased a new stake in DexCom in the 4th quarter worth $208,000. Gilbert & Cook Inc. lifted its position in shares of DexCom by 8.2% in the fourth quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after acquiring an additional 261 shares in the last quarter. Finally, Certuity LLC bought a new position in shares of DexCom in the fourth quarter worth about $453,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

Shares of DXCM traded down $0.28 during trading hours on Friday, reaching $69.34. 4,613,343 shares of the company traded hands, compared to its average volume of 3,777,717. The business has a fifty day moving average price of $90.92 and a 200-day moving average price of $114.58. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $27.58 billion, a P/E ratio of 44.74, a P/E/G ratio of 2.18 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.34 earnings per share. Equities analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on DXCM shares. BTIG Research reduced their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Redburn Atlantic began coverage on shares of DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective for the company. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday. Finally, Stifel Nicolaus increased their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold a total of 3,483 shares of company stock worth $369,052 in the last three months. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.